ArticleIndian dermatology online journal2026
Mucocutaneous Manifestations of Primary Systemic Amyloidosis: A Descriptive Study from Eastern India.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary systemic amyloidosis (PSA), also referred to as amyloid light-chain (AL) amyloidosis, is characterized by the deposition of insoluble monoclonal immunoglobulin light chains or L-chain fragments in a variety of tissues and organs of the body. There is a dearth of literature regarding the mucocutaneous manifestations of PSA in the Indian population, which prompted us to undertake the present study. AIM AND
objectiveWe aimed to study the clinical characteristics of mucocutaneous manifestations in patients with PSA at a tertiary care center in Kolkata. PATIENTS AND
methodsConsecutive patients with PSA, who presented to our facility with cutaneous features were included in this cross-sectional observational study done over 4 years.
resultsThe study involved 14 patients diagnosed with systemic amyloidosis (PSA) presenting with mucocutaneous symptoms. The mean age at diagnosis was 62.8 years, with a female-to-male ratio of 2:5. Myeloma-associated primary amyloidosis was identified in 35.7%. All patients showed pinch purpura, macroglossia, and tongue ridging. Periorbital purpura was seen in 92.8%, facial purpura in 85.7%, waxy nodules in 78.5%, xerosis in 57%, and diffuse alopecia in 35.7%. Relatively rare features included thickened skin, nail dystrophy, bullous lesions, lingual and subcutaneous nodules, atrophie blanche, and cutis laxa. Macular/lichen amyloidosis was also observed in one patient each. The head and neck were universally involved (100%). Eight patients had systemic features. LIMITATIONS: The study was limited by its hospital-based design, small sample size, and lack of lesional biopsies.
conclusionsPSA has a wide gamut of cutaneous features, and recognizing these skin lesions in the setting of PSA may be a significant clinical indicator of the underlying systemic illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.